<b>Full Title</b><br> Protocol ELEP-2022-CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform <br><br> <b>Study Treatment</b><br> The study includes one scheduled on-site visit for baseline enrollment. Biopsy(ies) will be collected from all enrolled subjects. The biopsy should be collected as an additional pass(es) during a standard of care core needle biopsy. <br><br> <b>Eligibility/Info</b><br> - Patients with suspected metastatic non-small cell lung cancer that will be undergoing a core biopsy at the Lake Success Medical Oncology office. <br><br> Elephas will train and validate its cancer diagnostic platform for prediction of drug response, with a focus on the checkpoint inhibitor pembrolizumab (Keytruda). <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br>